Derivation Web

source_458b3a5d57674ac2

by researka:v2 · 2026-06-20 00:34:54.251496+04:00

{"contradictions": ["Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that Alpha-glucosidase inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Aging is the dominant driver of chronic disease, frailty, and functional decline in older adults, and the question of whether pharmacological interventions can extend healthspan — the portion of life spent in good health — has become one of the most active questions in geriatric medicine (Studenski 2011). The demographic stakes are considerable: global life expectancy has risen steadily, yet the years lived with multimorbidity and mobility limitation have risen in parallel, motivating the search for interventions that compress morbidity rather than merely prolong survival (Cesari 2009). Functional markers such as gait speed, with small clinically meaningful changes on the order of 0.1 m/s (Perera 2006) and average annual declines near 0.05 m/s (Bohannon 1997), provide quantitative anchors against which any candidate geroprotector must eventually be judged. The economic and humanitarian case for delaying aging-related decline has therefore moved aging biology from a descriptive science to an interventional target, and the question of whether existing, widely used drugs can be repositioned to that end appears increasingly urgent. This synthesis is situated at that intersection: it asks what the current human evidence base does and does not say about acarbose as a candidate gerotherapeutic. Importantly, the evidence reviewed here may inform — but cannot by itself settle — the broader question of whether acarbose meaningfully alters human aging trajectories.", "The geroscience hypothesis proposes that targeting the biological mechanisms of aging — rather than any single disease — may simultaneously delay multiple age-related conditions, and that pharmacological modulation of those mechanisms is therefore a rational therapeutic strategy (Anisimov 2008). Within this framework, drug repurposing offers practical advantages: the safety, pharmacokinetic, and manufacturing profiles of approved agents are already characterized, potentially shortening the path from preclinical signal to human trial (Ioannidis 2005). This logic has energized systematic efforts to screen compounds originally developed for metabolic disease against canonical longevity endpoints, and acarbose has emerged as one of the candidates repeatedly highlighted in such programs. The geroscience framing also implies a hierarchy of evidence: mechanistic plausibility in model organisms is necessary but not sufficient, and the field has learned that surrogate biomarkers do not guarantee hard-outcome benefit (Ioannidis 2005). Accordingly, the translational bar for any repurposed agent is high — preclinical lifespan extension must be reconciled with human randomized evidence on clinically meaningful endpoints before claims of geroprotection can be entertained. The remainder of this introduction situates acarbose against that bar.", "The human randomized evidence landscape for acarbose is heterogeneous in design, population, and endpoint, ranging from mechanistic biomarker trials in type 2 diabetes to weight-management studies in overweight adults and pharmacodynamic bioequivalence work in healthy volunteers (Yang 2025; Holmback 2025; Lobato 2026). Several systematic reviews and meta-analyses have aggregated the cardiometabolic literature, reporting signals on triglycerides, total cholesterol, and postprandial blood pressure that are directionally favorable but variable in magnitude and statistical certainty (Yousefi 2023; Wang 2021; Madden 2025). The central interpretive challenge is therefore that acarbose has been studied in many trials, but rarely in trials whose primary endpoint is aging itself; the question of whether the existing human RCT evidence, Across the corpus, supports a geroprotective claim remains, as the field acknowledges, unsettled.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Mechanistically, the survival disadvantage reported for acarbose in female crickets can be read against the canonical acarbose pharmacology of intestinal α-glucosidase inhibition and consequent blunting of post-prandial glucose excursions, a substrate-level mechanism that has been linked in mammalian mechanistic human studies and preclinical data to attenuated glycaemic load and downstream mTOR-related nutrient-sensing pathways (Liao 2025). In the cricket model, however, the same pharmacological class appears to act in the opposite direction on survival, which suggests that the gerotherapeutic translation of α-glucosidase inhibition is not species-invariant and may depend on baseline dietary carbohydrate composition, sex-specific metabolic set-points, or microbiome composition that differs between orthopterans and mammals. The mechanistic substrate underlying this functional finding therefore cannot be cleanly extrapolated from the Liao 2025 invertebrate signal to human longevity, and any mechanistic narrative must be qualified as preclinical, sex-stratified, and non-mammalian in origin. Preclinical data from this systematic review thus function here as a hypothesis-generating boundary condition rather than as confirmatory human-relevant evidence."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "08943c0f-97ab-41e2-820b-bf2dbe384513", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 14, "included": 14, "included_or_retained": 14, "screened": 14, "wording": "14 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "08943c0f-97ab-41e2-820b-bf2dbe384513",
  "researka_submission_id": "c692a542-ec48-4973-8fc0-452c722f7c5d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/08943c0f-97ab-41e2-820b-bf2dbe384513/sidecars/contradiction_map.json"
}